Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 17, 2011

miR-34a Found to Suppress Prostate Cancer Stem Cells

  • A group of researchers have demonstrated that miR-34a inhibits prostate cancer tumor-initiating cells by suppressing CD44, a cell surface protein prevalent on cancer cells. The research was conducted by scientists at the University of Texas MD Anderson Cancer Center and Mirna Therapeutics. miR-34a is one of eight miRNAs in preclinical development by the company.

    “Our findings are the first to profile a microRNA expression pattern in prostate cancer stem cells and also establish a strong rationale for developing the microRNA miR-34a as a new treatment option for prostate cancer,” says senior author, Dean Tang, Ph.D., professor in MD Anderson's department of molecular carcinogenesis.

    The paper, “The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44,” is published in Nature Medicine.

    The study demonstrated that miR-34a was under-expressed in CD44+ prostate cancer cells purified from xenograft and primary tumors. Enforced expression of miR-34a in bulk or purified CD44+ prostate cancer cells inhibited clonogenic expansion, tumor regeneration, and metastasis.

    When miR-34a antagomirs were expressed in CD44- cancer cells, tumor development and metastasis was promoted. Also, when miR-34a was systemically delivered, it inhibited prostate cancer metastasis and extended the survival of tumor-bearing mice. The researchers concluded that miR-34a is a key negative regulator of CD44+ prostate cancer cells.

    “CD44 has long been linked to promotion of tumor development and, especially, to cancer metastasis,” says Dr. Tang. “Many cancer stem cells over-express this surface adhesion molecule. Another significant finding from our study is identifying CD44 itself as a direct and functional target of miR-34a.”

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »